Evidence map›Paper›PMID 24813918›Full record

ArticleLeukemia2014

Circulating miRNA markers show promise as new prognosticators for multiple myeloma.

A Rocci, C C Hofmeister, S Geyer, A Stiff, M Gambella, L Cascione, J Guan, D M Benson, Y A Efebera, T Talabere and 22 more

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Leukemia, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Targeting microRNA in hematologic malignancies.Current opinion in oncology · 2020
    Review
  16. Article
  17. Liquid biopsies for multiple myeloma in a time of precision medicine.Journal of molecular medicine (Berlin, Germany) · 2020
    Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

32 authors.

A RocciMyeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy.
C C HofmeisterDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.
S GeyerDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.
A StiffDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.
M GambellaMyeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy.
L Cascione1] Molecular Virology, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA [2] Lymphoma & Genomics Research Program, Institute of Oncology Research-IOR, Bellinzona, Switzerland.ORCID 0000000246060637
J GuanMolecular Virology, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
D M BensonDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.
Y A EfeberaDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.
T TalabereDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.
V DirisalaDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.
E M SmithDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.
P OmedèMyeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy.
G IsaiaDepartment of Clinical and Biological Sciences, Division of Geriatric, S. Luigi Gonzaga Hospital, University of Torino, Torino, Italy.
L De LucaLaboratory of Preclinical and Translational Research, IRCCS-Referral Cancer Center of Basilicata (CROB), Rionero in Vulture, Italy.
D RossiDivision of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy.
S GentiliItalian Multiple Myeloma Network, GIMEMA, Italy.
G UccelloItalian Multiple Myeloma Network, GIMEMA, Italy.
J ConsiglioDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.
R RiaItalian Multiple Myeloma Network, GIMEMA, Italy.
G BenevoloItalian Multiple Myeloma Network, GIMEMA, Italy.
S BringhenMyeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy.
V CalleaItalian Multiple Myeloma Network, GIMEMA, Italy.
B WeissAbramson Cancer Center, Division of Hematology-Oncology, University of Pennsylvania, Philadelphia, PA, USA.
A FerroDepartment of Clinical and Molecular Biomedicine, University of Catania, Catania, Italy.
V MagarottoMyeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy.
H AlderMolecular Virology, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
J C ByrdDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.
M BoccadoroDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.
G MarcucciMyeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy.
A PalumboMyeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy.
F PichiorriDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.

Funding

Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Tasleem J Padamsee · 1985 to 2026
$132.3M
NCI NIH HHS P30 CA016058
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

BiomarkersDisease-Free SurvivalHumansMicroRNAsMultiple MyelomaPrognosisProportional Hazards ModelsBiomarkersMicroRNAs

Identifiers

PMID24813918
PMCPMC4155011

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.